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Parenteral iron therapy exacerbates experimental sepsis
Rapid Communication
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Parenteral iron therapy exacerbates experimental sepsis.
Background. Catalytic iron can potentiate systemic inflam-
mation via its pro-oxidant effects. This raises the possibility that
parenteral iron administration might exacerbate a concomi-
tant septic state. This study sought to experimentally test this
hypothesis.
Methods. Male CD-1 mice were subjected to experimental
sepsis via intraperitoneal injection of heat-killed Escherichia
coli ± concomitant intravenous iron sucrose (Venofer; 2 mg).
Nonseptic mice ± iron therapy served as controls. Plasma tumor
necrosis factor-a (TNF-a) levels were assessed 2 hours postin-
jections (serving as an inflammatory marker). Oxidative stress
was gauged in heart or kidney tissue (at either 4 or 24 hours)
by heme oxygenase-1 (HO-1) mRNA or protein levels. Over-
all sepsis severity was assessed by morbidity/mortality rates
(at 24 hours).
Results. Iron alone or sepsis alone each induced oxidant stress
in heart and kidney (HO-1 mRNA/protein increases). When
iron and E. coli were coadministered, additive or synergistic
HO-1 mRNA/protein increments resulted. Iron injection alone
only slightly raised TNF-a levels (from 0 to 2.3 pg/mL; P = 0.01).
However, iron approximately doubled the TNF-a increments
which arose from the septic state (1400 → 2600 pg/mL). Neither
sepsis alone, nor iron alone, induced any mortality and no mice
became moribund (0/24 mice). However, when iron + sepsis
were combined, ∼60% of mice either died (5/12) or developed
a moribund (2/12) state (P = 0.005).
Conclusion. Parenteral iron administration can induce sys-
temic oxidative stress and modest TNF-a release. However,
when iron is given during experimental sepsis, profound in-
creases in both processes, and ∼60% mortality, result. Given
that renal failure patients have decreased antioxidant defenses
and intermittently develop bacteremia, the potential for par-
enteral iron therapy to exacerbate clinical sepsis needs to be
addressed.
Systemic inflammation is believed to be an impor-
tant determinant of morbidity and mortality in patients
with end-stage renal disease (ESRD). This concept is
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underscored by observations that serum C-reactive pro-
tein (CRP) levels, a surrogate marker of systemic in-
flammation, directly correlate with dialysis-associated
complications (e.g., adverse cardiovascular events [1–5]).
Oxidative stress, which can be driven by catalytic (free)
iron, can promote inflammation via a number of poten-
tial pathways. For example, redox-sensitive transcription
factors, such as nuclear factor-kappaB (NF-jB), cFos,
c-Jun, activated protein-1 (AP-1), and hypoxia-inducible
factor-1a (HIF-1a), are up-regulated by oxidative states
[6–9]. Once activated, these molecules can recruit a va-
riety of “downstream” inflammatory mediators, such as
tumor necrosis factor-a (TNF-a), cytokine receptors, and
adhesion molecules [10]. That antioxidants can attenuate
NF-jB and AP-1 expression, and thus, suppress inflam-
mation, supports this pathophysiologic link [11–15].
Parenteral iron formulations are routinely adminis-
tered to hemodialysis patients to help correct anemia.
However, currently employed iron preparations can each
exert potent pro-oxidant effects [16–22]. Given these con-
siderations, it seems feasible that their administration
might predispose to life-threatening acute systemic in-
flammation, most notably as induced by sepsis. This study
was undertaken to test this hypothesis.
METHODS
Sepsis model
For this study, an experimental sepsis model was em-
ployed which involves the intraperitoneal injection of
nonviable (boiled) Escherichia coli. This model induces
the manifestations of sepsis, while avoiding the confound-
ing variables which may result from in vivo bacterial
replication [23–25]. Boiling does not denature endotoxin,
which remains intact in the bacterial cell wall. Thus,
the administration of heat-killed organisms should more
accurately simulate a bacterial-induced endotoxin chal-
lenge than would soluble, purified, endotoxin injection.
Male CD-1 mice (25 to 35 g) (Charles River Laboratories,
Wilmington, MA, USA) were used for all experiments.
They were placed in restrainers and divided into one
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of four treatment groups: (1) Controls: 100 lL tail vein
injection of 0.9% saline (sham for IV iron treatment); (2)
IV Fe injection: 2 mg elemental Fe3+, given in the form
of Fe sucrose (Venofer; American Regent, Shirley, NY,
USA); (3) Sepsis syndrome: IP injection of 2 mL of a heat
killed E. coli slurry, containing ∼1 × 109 organisms per
mL of saline [23]; additionally, 100 lL of saline was in-
jected via the tail vein as a sham for IV iron treatment
(see group 4); and (4) Sepsis + Fe injection: IV Fe su-
crose followed immediately by IP E. coli injection. The
mice were then returned to their cages and given free
food and water access. Assessments were made at 2, 4, or
24 hours later, as described below.
Survival, renal cortical heme oxygenase-1 (HO-1)
protein levels: 24-hour assessments
Mice subjected to each of the above treatments (N = 12
per each group) were evaluated using one of the follow-
ing criteria: (1) survival; (2) survival, but in an obvious
moribund state (no spontaneous movement, decreased
body temperature to touch, decreased respiration); or
(3) death. All surviving animals were deeply anesthetized
with pentobarbital (3 to 4 mg intraperitoneally), followed
by a midline laparotomy, terminal phlebotomy [from the
inferior vena cava (IVC)], and bilateral renal resection.
Renal cortical protein extracts were probed by West-
ern blot for HO-1 protein [26] as a marker of oxidant
tissue stress [27, 28]. Renal insufficiency was quantified
by blood urea nitrogen (BUN) and plasma creatinine
concentrations.
Renal cortical and cardiac oxidant stress:
4-hour assessments
The above mouse protocols were repeated (N = 6
animals per group), followed 4 hours later by induc-
tion of pentobarbital anesthesia. The kidneys and heart
were removed through abdominal and thoracic incisions,
respectively. Total RNA was extracted from renal cor-
tical and cardiac apex tissue samples, followed by re-
verse transcription-polymerase chain reaction (RT-PCR)
for quantifying HO-1 mRNA and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA levels, as
previously described [26]. The ratio of HO-1 mRNA/
GAPDH mRNA, assessed by densitometry, served
as a semiquantitative marker of oxidative tissue
stress.
Systemic inflammatory response: TNF-a levels at 2 hours
posttreatment
The four above-described protocols were repeated
(N = 5 mice per group). Two hours later, the mice were
anesthetized and subjected to terminal phlebotomy from
the IVC. The severity of the systemic inflammatory re-
sponse was gauged by plasma TNF-a concentrations [by
enzyme-linked immunosorbent assay (ELISA)] (R&D
Systems, Minneapolis, MN, USA).
Statistics
All values are presented as means ± 1 SEM. Statis-
tical comparisons were performed by unpaired Student
t test, unless stated otherwise. Significance was judged by
a P value of <0.05.
RESULTS
24-hour analyses
Survival rates. All of the mice which received either
E. coli alone (N = 12) or intravenous iron alone (N = 12)
survived the protocols and none in either group appeared
moribund. In contrast, in the iron+ sepsis group, five mice
died and two were moribund. Thus, 7/12 of mice in the
iron + sepsis group were either moribund or dead vs. 0/12
in the sepsis only group (P = 0.005 by Fisher’s exact test).
Renal function. Neither iron alone nor sepsis alone
raised plasma creatinine concentrations above control
levels. However, when these two challenges were com-
bined, significant plasma creatinine elevations resulted
(Fig. 1A). Sepsis raised BUN concentrations to 55 ±
10 mg/dL (P < 0.02 vs. control values) (Fig. 1B). Sepsis +
iron raised BUNs to 81 ± 13 mg/dL. While higher than
sepsis alone, this degree of BUN elevation did not achieve
statistical significance [Note: The BUN and creatinine
levels could not be determined for the five mice which
died from the combined sepsis + iron protocol. Given
that these animals were obviously the sickest, the exclu-
sion of their BUN/creatinine values most likely caused
an underestimate of the severity of renal insufficiency in
the iron + sepsis group].
HO-1 Western blotting. Fe sucrose alone caused a
modest increase in HO-1 protein expression (Fig. 2,
lane 3) (P < 0.02 vs. controls). Sepsis alone did not sig-
nificantly increase HO-1 levels (lane 4). However, when
iron and sepsis were combined, a striking increase in HO-
1 expression resulted (P < 0.001 vs. iron alone; consistent
with synergistic oxidative stress). To assess the relative
degree of HO-1 protein induction by the iron + sepsis
protocol, it was contrasted with that observed in a renal
cortical protein extract prepared from a mouse 24 hours
postinduction of severe, glycerol- induced, rhabdomyol-
ysis acute renal failure (BUN 212 mg/dL), an insult which
is known to profoundly increase HO-1 protein levels [27,
28]. The level of HO-1 protein observed post glycerol
was comparable to that seen following the sepsis + iron
challenge (lane 5). This confirms the severity of HO-1
induction in the iron + sepsis group.
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Fig. 1. Plasma creatinine and blood urea nitrogen (BUN) concentrations 24 hours following iron sucrose (Fe) injection, induction of sepsis
syndrome, or the combination thereof. (A) Neither iron nor sepsis alone induced significant plasma creatinine elevations, compared to the controls.
Conversely, combined iron + sepsis caused an approximate doubling of the plasma creatinine concentration. (B) Sepsis alone, but not iron alone,
caused a significant increase in BUN concentrations. Combination iron + sepsis was associated with higher BUNs than either treatment alone, but
this difference did not achieve statistical significance [as noted in the Results section, five of 12 mice in the iron + sepsis group died prior to blood
sampling; this likely caused an underestimate of the severity of BUN and creatinine elevations in this group].
4-hour analyses
HO-1 mRNAs. Iron alone and sepsis alone each
caused a significant increase in HO-1 mRNA in both re-
nal cortex and cardiac apex (Table 1). When sepsis +
iron were combined, significantly greater HO-1 mRNA
increases were observed in both tissues, compared to val-
ues observed with either iron or sepsis alone.
TNF-a assessments at 2 hours after iron/sepsis protocols
TNF-a could not be detected in plasma from control
animals. Iron injection caused modest TNF-a increments
(mean, 2.29 pg/mL) (see Table 1). Sepsis caused striking
TNF-a elevations (mean, 1446 pg/mL). The degree of
this sepsis-induced TNF-a increase was approximately
doubled by concomitant iron treatment (to 2600 pg/mL)
(Table 1).
DISCUSSION
This brief report provides experimental support for the
concept that intravenous iron administration can acutely
trigger oxidative stress, and that by so doing, it can exac-
erbate a superimposed, sepsis-triggered, severe systemic
inflammatory event. These principles are indicated by the
following pieces of evidence. First, within 4 hours of in-
travenous iron injection, HO-1 mRNA increments were
noted in both myocardium and renal cortex, consistent
with multiorgan-based oxidative stress [27, 28]. Second,
at 24 hours, renal cortical HO-1 protein increments re-
sulted, indicating the functional significance of the HO-1
mRNA induction. Third, with concomitant E. coli ad-
ministration, iron induced either additive or synergistic
HO-1 mRNA/protein increments. Finally, although intra-
venous iron injection induced seemingly trivial plasma
TNF-a increments, it approximately doubled the TNF-a
elevations which resulted from the experimental septic
state. By itself, E. coli “sepsis” caused no mortality, with
all animals surviving in a relatively healthy state. How-
ever, with iron coadministration, E. coli “sepsis” induced
an approximate 50% to 60% mortality rate. Clearly then,
the above evidence of additive/synergistic oxidative stress
and cytokine (TNF-a) release, evinced by the combined
sepsis + iron challenge, had marked biologic relevance
as assessed at the whole animal level.
Given that a suprapharmacologic iron dosage was
used in these experiments, clinical relevance cannot
be ascribed to the present observations. However, nei-
ther should this possibility simply be dismissed. In
this regard, it is noteworthy that ESRD patients have
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Fig. 2. Heme oxygenase 1 (HO-1) in renal
cortex, as assessed by Western blotting (den-
sitometry readings). Samples were obtained
24 hours postinduction of the iron (Fe), sep-
sis, or iron + sepsis protocols, and the results
were compared to control tissues (C). Iron
caused a significant increase in HO-1 expres-
sion, compared to controls (∗P < 0.02). Sepsis
alone did not cause obvious HO-1 induction.
However, sepsis + iron caused an approxi-
mate 3 × increase in HO-1, compared to val-
ues observed with iron treatment alone (∗∗P
< 0.001). Representative blots are presented
under each bar. As a comparison for the iron
+ sepsis result, a Western blot of renal cortex
obtained 24 hours postinduction of glycerol
(gly) induced-rhabdomyolysis nephrotoxicity
(BUN, 212 mg/dL) is presented. The post-
glycerol result and the iron + sepsis result
were comparable (underscoring the severity
of the HO-1 induction seen in the iron + sep-
sis group).
Table 1. Heme oxygenase (HO-1) mRNA and tumor necrosis
factor-a (TNF-a) assessments following the induction of the
experimental protocols
Iron Sepsis +
End point Controls sucrose Sepsis iron
HO-1 mRNA 0.64 ± 0.4 1.34 ± 0.02a 1.08 ± 0.04a 1.73 ± 0.15b
(kidney)
HO-1 mRNA 0.30 ± 0.01 0.68 ± 0.07a 0.51 ± 0.05a 0.83 ± 0.07b
(heart)
Plasma TNF-a 0.00 2.29 ± 0.56c 1446 ± 161c 2600 ± 484d
pg/mL
HO-1 mRNAs in heart and kidney were assessed 4 hours posttreatment.
aAll three treatment groups significantly differed from the controls (P < 0.01);
bThe sepsis + iron sucrose group had significantly higher renal cortical and cardiac
HO-1 mRNA values than either the iron alone (P < 0.05) or the sepsis alone
(P < 0.001) group. TNF-a levels were assessed 2 hours after iron or Escherichia
coli injections; cP < 0.01 by Wilcoxon rank sum test (controls 0 vs. iron treatment);
dSepsis vs. sepsis + iron, P < 0.05.
diminished antioxidant defenses, presumably sensitizing
them to pro-oxidative states [29–32]. Furthermore, fol-
lowing iron injection, clinical oxidative stress is known
to result [17–22]. Iron is also a growth factor for many
bacteria [33], enhancing in vivo proliferation. Parenteral
iron formulations can also impair neutrophil migration
[34], impairing host defenses. Thus, these considerations,
along with the current findings, suggest multiple pathways
by which intravenous iron therapy might potentiate sep-
sis, and the “downstream” inflammatory consequences
thereof.
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